BCD Bioscience Raises $12M In Series A Funding to Develop Lead Products

BCD Bioscience, a biotechnology company creating precision prebiotics from natural fibers, has completed an oversubscribed Series A financing round of $12 million led by Acre Venture Partners. Existing investors, Seventure Partners and iSelect Fund, upped their commitments for the round and new investors, Collaborative Fund and Skyviews Life Science, have joined.

The financing will be used to obtain regulatory approvals for lead products, upscale production capabilities, expand the product pipeline, and to continue to build out the prediction and screening platform. CEO Steve Watkins said, “We are extremely pleased to have secured the financing needed to convert our promising lead prebiotics into high-value products and commercial opportunities. I am also delighted that our ability to deliver during our seed phase in creating our prebiotic library, screening platform, and pipeline gave such confidence to our investors.”

“We are thrilled to have partnered with Steve and the entire BCD team. Their unique platform and precision prebiotics will be critical in advancing public health, as well as contributing to reducing waste in our food systems. As this space continues to evolve, BCD will play a critical role, not only in functional foods and medical nutrition, but also in therapeutics,” said Gareth Asten, Managing Partner at Acre Venture Partners.